Haemophilia therapies

Expert Opinion on Biological Therapy

Volumn 7, Issue 5, 2007, Pages 651-663

  Dargaud, Yesim ^a   Negrier, Claude ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bypassing agents; FIX; FVIII; Gene therapy; Global haemostasis tests; Haemophilia

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ADENOVIRUS VECTOR; BETAFACT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CD20 ANTIBODY; EMOCLOT DI; FACTANE; FANHDI; HELIXATE FS; KOATE DVI; NOVIX; OCTANATE; OCTANINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE HEART INFARCTION; BIOENGINEERING; BLEEDING; BLOOD CLOTTING TEST; BREATHING DISORDER; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FEVER; FLUSHING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HALF LIFE TIME; HEART INFARCTION; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IMMUNOADSORPTION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LOW DRUG DOSE; MEDICAL PROFESSION; NAUSEA; NONHUMAN; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THORAX PAIN; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANIMALS; BLOOD COAGULATION FACTORS; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FACTOR IX; FACTOR VII; FACTOR VIII; GENE THERAPY; HEMOPHILIA A; HEMORRHAGE; HUMANS; PATIENT SELECTION; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 34248176342     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.5.651     Document Type: Review

References (143)

1. MANNUCCI PM, TUDDENHAM EG: The hemophilias-from royal genes to gene therapy. N. Engl. J. Med. (2001) 344:1773-1780.
2. ROSNER F: Haemophilia in the Talmud and rabbinic writings. Ann. Intern. Med. (1969) 70:833-837.
3. LANE S: Haemorrhagid diarhesis. Successful transfusion of blood. Lancet (1840) 1:185-188.
4. PAYNE WW, STEEN RE: Haemostatic therapy in haemophilia. Br. Med. J. (1929) 29(1):1150-1152.
5. BRINKHOUS KM: A study of the clotting defect in hemophilia : the delayed formation of thrombin. Am. J. Med. Sci. (1939) 198:509-516.
6. BIGGS R, DOUGLAS AS, MACFARLANE RG, DACIE JV, PITNEY WR, MERSKEY C: Christmas disease: a condition previously mistaken for hemophilia. Br. Med. J. (1952) 2:1378-1382.
7. CRAMER R, FLÜCKIGER P, GASSER C, KOLLER F, LOELIGER A, MATTER M: Two cases of hereditary hemophilia due to a deficiency of a new clotting factor (Christmas factor). Acta Haematol. (1953) 10:65-76.
8. MANNUCCI PM: AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. J. Thromb. Haemost. (2003) 1:2065-2069. •• An excellent review of the infectious complications in haemophilia patients.
9. EVATT BL, FARUGGIA A, SHAPIRO AD, WILDE JT: Haemophilia 2002: emerging risks of treatment. Haemophilia (2002) 8:221-229.
10. ROYAL S, SCHRAMM W, BERNTORP E et al.: Quality of life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia (2002) 8:44-50.
11. MANNUCCI PM: Haemophilia:treatment options in the twenty-first century. J. Thromb. Haemost. (2003) 1:1349-1355. •• An excellent comprehensive review on haemophilia treatment.
12. BURNOUF T, RADOSEVICH M: Nanofiltration of plasma derived biopharmaceutical products. Haemophilia (2003) 9:24-37.
13. BUSCH MP, KLEINMAN SH, JACKSON B, STRAMER SL, HEWLETT I, PRESTON S: Commitee report. Nucleic acid testing of blood donors for transfusion- transmitted infectious diseases: report of the Interorganizational task force on nucleic acis amplification testing of blood donors. Transfusion (2000) 40:143-159.
14. GOUDEMAND J, ROTSCHILD C, DEMIGUEL V et al.: Influence of the type of Factor VIII concentrate on the incidence of Factor VIII inhibitors in previously untreated patients with severe hemophilia A. FVIII-LFB and Recombinant FVIII Study Groups. Blood (2006) 107:46-51.
15. BEHRMANN M, PASI J, SAINT-REMY JM et al.: Von Willebrand factor modulates Factor VIII immunogenicity: comparative study of different Factor VIII concentrates in a haemophilia A mouse model. Thromb. Haemost. (2002) 88:221-229.
16. KERNOFF PB, DURANT IJ, RIZZA CR, WRIGHT FB: Severe allergic pulmonary oedema after plasma transfusion. Br. J. Haematol. (1972) 23:777-781.
17. GIANGRANDE PLF: Treatment of haemophilia: recombinant factors only? Yes. J. Thromb. Haemost. (2003) 1:214-215.
18. GITSCHIER J, WOOD WI, GORALKA TM et al.: Characterization of the human Factor VIII gene. Nature (1984) 312:326-330.
19. TOOLE JT, KNOPF JL, WOZNEY JM et al.: Molecular cloning of a cDNA encoding human anti-haemophilic factor. Nature (1984) 312:342-347.
20. SCHWARTZ RS, ABILDGAARD CF, ALEDORT LM et al.: Human recombinant DNA-derived antihaemophilic factor (Factor VIII) in the treatment of haemophilia A. N. Engl J. Med. (1990) 323:1800-1805.
21. BOEDEKER BG: Production processes of licensed recombinant factor FVIII preparations. Semin. Thromb. Haemost. (2001) 274:385-394.
22. BRINKHOUS K, SANDBERG H, WIDLUND L et al.: Preclinical pharmacology of albumin-free B domain deleted recombinant Factor VIII. Semin. Thromb. Haemost. (2002) 28:269-272.
23. TOOLE JT, PITTMAN DD, ORR EC et al.: A large region (=95kDa) of human Factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. USA (1986) 83:5839-5842.
24. LUSHER JM, LEE CA, KESSLER CM, BEDROSIAN CL: The safety and efficacy of B domain deleted recombinant Factor VIII concentrate in patients with severe haemopihilia A. For the REFACTO 3 Study Group. Haemophilia (2003) 9:38-49.
25. GRUPPO RA, BROWN D, WILKES MM, NAVICKIS RJ: Increased breaktrough bleeding during prophylaxis with B-domain deleted Factor VIII - a robust meta-analytic finding. Haemophilia (2004) 10:449-451.
26. MITTERER A, KALIWODA M, KUMAR HP, KASHI RS: Recombinant Factor VIII manufactured without the use of animal/human derived substances (rAHF-PFM). Blood (2002) 100:92b (Abstract).
27. CHOO KH, GOULD KG, REES DJ, BROWNLEE GG: Molecular cloning of the gene for human anti-haemophilic Facror IX. Nature (1982) 299(5879):178- 180.
28. ANSON DS, CHOO KH, REES DJ et al.: The gene structure of human anti-haemophilic Factor IX. EMBO J. (1984) 3:1053-1060.
29. HAASE M: Human recombinant Factor IX: safety and efficacy studies in haemophilia B patients previously treated with plasma derived Factor IX concentrates. Blood (2002) 100:4242; author reply 4242-4243.
30. WHITE G, SHAPIRO A, RAGNI M et al.: Clinical evaluation of recombinant Factor IX. Semin. Hematol. (1998) 35(Suppl. 2):33-38.
31. WHITE GC II, COURTER S, BRAY GL, LEE M, GOMPERTS ED: A multicentre study of recombinant Factor VIII (Recombinate) in previously treated patients with hemophilia A. Thromb. Haemost. (1997) 77:660-667.
32. SCHARRER I, BRAY GL, NEUTZLING O: Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived FVIII concentrates. Haemophilia (1999) 5:145-154.
33. BRAY GL, GOMPERTS ED, COURTER S et al.: A multicentre study of recombinant Factor VIII (Recombinate): safety, efficacy and inhibitor risk in perviously untreated patients with haemophilia A. Blood (1994) 83:2428-2435.
34. LUSHER JM, ARKIN S, ABILGAARD CF: Kogenate previously untreated patient study group. Recombinant afctor VIII for the treatment of previously untreated patients with haemophilia A: safety, efficacy and development of inhibitors. N. Engl. J. Med. (1993) 328:453-459.
35. EHRENFORTH S, KREUZ W, SCHARRER I et al.: Incidence of development of factor FVIII and FIX inhibitors in haemophiliacs. Lancet (1992) 339:594-598.
36. RODRIGUEZ-MERCHAN EC: Orthopedic surgery in persons with haemophilia. Thromb. Haemost. (2003) 89:34-42. •• An excellent discussion on the issues regarding the orthopaedic problems of haemophilia patients.
37. FISCHER K, VAN DER BERG M: Prophylaxis for severe hamophilia: clinical and economical issues. Haemophilia (2003) 9:376-381.
38. PETRINI P, LINDVALL N, EGBERG N, BLOMBACK M: Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am. J. Pediatr. Hematol. Oncol. (1991) 13:280-287.
39. LOFFQVIST T, NILSSON IM, BERNTORP E, PETTERSSON H: Haemophilia prophylaxis in young patients - a long term follow up. J. Intern. Med. (1997) 241:395-400.
40. FISCHER K, VAN DER BOM M, NEGRIER C et al.: Prophylactic versus on demand treatment strategies for severe haemophilia: a comparison of costs and long term outcome. Haemophilia (2002) 8:1365-2516.
41. LJUNG RC: Prophylactic treatment in Sweden - overtreatment or optimal model? Haemophilia (1998) 4:409-412.
42. BERNTORP E, BOULYJENKOV V, BRETTLER D et al.: Modern treatment of haemophilia. Bull. World Health Organ. (1995) 73:691-701.
43. LJUNG R, VAN DER BERG M, PETRINI P et al.: Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Pediatr. (1998) 87:1051-1054.
44. TUSELL J, PEREZ-BIANCO R: Prophylaxis in developed and in emerging countries. Haemophilia (2002) 8:183-188.
45. FELDMAN BM, RIVARD G, ISRAELIS S et al.: Preliminary results from the Canadian hemophilia prophylaxis trial. Haemophilia (2000) 6:272.
46. ALEDORT LM: Why thrombin generation? From bench to bedside. Pathophysiol. Haemost. Thromb. (2003) 33:2-3.
47. THE MEDICAL AND SCIENTIFIC ADVISORY COUNCIL (MASAC): MASAC Recommendations Concerning Prophylaxis. MASAC Document #170. 22 April 2006, and adopted by the National Hemophilia Foundation Board of Directors on 3 June 2006 (2006).
48. KULKARNI R, PONDER KP, JAMES AH et al.: Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a white paper of the Perinatal Task Force of THE Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. Haemophilia (2006) 12:205-211.
49. VAN DER BERG HM, FISCHER K, ROSENDAAL G, MAUSER-BUNSCHOTEN EP: The use of the Port-A-Cath in children with haemophilia-a review. Haemophilia (1998) 4:418-420.
50. VIDLER V, RICHARDS M, VORA A: Central venous catheter associated thrombosis in severe haemophilia. Br. J. Haematol. (1999) 104:461-464.
51. BLANCHETTE VS, AL-TRABOLSI H, STAIN AM: High risk of central venous line-associated thrombosis in boys wirh hemophilia. Blood (1999) 94:818a (Abstract).
52. JOURNAYCAKE JM, QUINN CT, MILLER KL, ZAJAC JL, BUCHANAN GR: Catheter related deep venous thrombosis in children with hemophilia. Blood (2001) 98:1727-1731.
53. LJUNG R: Central venous lines in haemophilia. Haemophilia (2003) 9(Suppl. 1):88-93.
54. BOHN RL, AVORN J, GLYNN RJ, CHOODNOVSKIY I, HASCHEMEYER R, ALEDORT LM: Prophylactic use of Factor VIII: an economic evaluation. Thromb. Haemost. (1998) 79:932-937.
55. WIGHT J, PAISLEY S: The epidemiology of inhibitors in haemophilia A: a systemic review. Haemophilia (2003) 9:418-435.
56. ASTERMARK J: Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia (2006) 12(Suppl. 3):52-60.
57. SAINT REMY JM, LACROIX DESMAZES S, OLDENBURG J: Inhibitors in mhaemophilia: pathophysiology. Haemophilia (2004) 10(Suppl. 4):146-151.
58. WHITE GC II, KEMPTON CL, GRIMSLEY A, NIELSEN B, ROBERTS R: Cellular immune responses in haemophilia: why do inhibitors develop in some, but not all haemophiliacs? J. Thromb. Haemost. (2005) 3:1676-1681. • An excellent discussion of inhibitors.
59. LEISSINGER CA: Prevention of bleeds in hemophilia patients with inhibitors:emerging data and clinical direction. Am. J. Hematol. (2004) 77:187-193.
60. ABILDGAARD CF, PENNER JA, WATSON-WILLIAMS EJ: Anti inhibitor coagulant complex (Autoplex) for treatment of Factor VIII inhibitors in haemophilia. Blood (1980) 56:978-984.
61. LUSHER JM, BLATT PM, PENNER JA et al.: Autoplex versus Proplex: a controlled, double-blind study of effectiveness in acute haemarthroses in haemophiliacs with inhibitors to Factor VIII. Blood (1983) 62:1135-1138.
62. TURECEK PL, VARADI K, GRITSCH H, SCHWARZ HP: Activated prothrombin complex concentrates induce haemostasis by a balanced effect at multiple sites of the coagulation pathway. Haemophilia (1998) 4:168 (Abstract).
63. VON DEPKA M: Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety. Haemophilia (2005) 11(Suppl. 1):18-23.
64. WILDE JT: Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors. Pathophysiol. Haemost. Thromb. (2002) 32(Suppl. 1):9-12.
65. SJAMSOEDIN LJ, HEIJNEN L, MAUSER-BUNSCHOTEN EP et al.: The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to FVIII. A double blind clinical trial. N. Engl. J. Med. (1981) 305:717-721
66. HILGARTNER MW, KNATTERUD GL: The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitors. Blood (1983) 61:36-40.
67. HILGARTNER M, ALEDORT L, ANDES A, GILL J: Efficacy ans safety of vapour heated anti-inhibitor coagulant complex in haemophilia patients. FEIBA study group. Transfusion (1990) 30:626-630.
68. NEGRIER C, GOUDEMAND J, SULTAN Y, BERTRAND M, ROTHSCHILD C, LAUROUA P: Multicentre retrospective study on the utilization of FEIBA in France in patients with Factor VIII and Factor IX inhibitors. French FEIBA study Group. Factor Eight Bypassing Activity. Thromb. Haemost. (1997) 77:1113-1119. • An important article discussing the use of FEIBA.
69. HAY CR, BAGLIN TP, COLLINS PW et al.: The diagnosis and management of Factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br. J. Haematol. (2000) 111:78-90.
70. EHRLICH HJ, HENZL M, GOMPERTS ED: Safety of FVIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia (2002) 8:83-90.
71. HAY CR, BAGLIN TP, COLLINS PW, HILL FG, KEELING DM: The diagnosis and management of Factor VIII and Factor IX inhibitors: a guideline from UK haemophilia center Doctors' organisation (UKHCDO). Br. J. Haematol. (2000) 111:78-90.
72. HORWITH G, REVIE DR: Efficacy of viral clearance methods used in the manufacture of activated prothrombin complexe concentrates: focus on Autoplex T. Haemophilia (1999) 5(Suppl. 3):19-23.
73. SJAMSOEDIN LJ, HEIJNEN L, MAUSER-BUNSCHOTEN EP et al.: The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to Factor VIII. N. Engl. J. Med. (1981) 305:717-721.
74. VARADI K, NEGRIER C, BERNTORP E et al.: Monitoring the bioavailability of FEIBA with a thrombin generation assay. J. Thromb. Haemost. (2003) 1:2374-2380.
75. DARGAUD Y, LIENHART A, MEUNIER S et al.: Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia (2005) 11(5):552-558.
76. YOUNG G, BLAIN R, NAKAGAWA P, NUGERT DJ: Individualization of bypassing agent treatment for hemophilic patients with inhibitors utilizing thromboelastography. Haemophilia (2006) 12:598-604.
77. MONROE DM, HOFFMAN M, OLIVER JA et al.: Platelet activity of high dose Factor VIIa is independent of tissue afctor. Br. J. Haematol. (1997) 99:542-547.
78. FRANCHINI M, ZAFFANELLO M, VENERI D: Recombinnat FVIIa. Thromb. Haemost. (2005) 93:1027-1035.
79. VAN'T VEER C, GOLDEN NJ, MANN KG: Inhibition of thrombin generation by the zymogen Factor VII: implications for the treatment of hemophilia A by Factor VIIa. Blood (2000) 95:1330-1335.
80. HOFFMAN M: A cell based model of haemostasis. Blood Rev. (2003) 17:S1-S5.
81. LISMAN T, MOSNIER LO, LAMBERT T et al.: Inhibition of fibrinolysis by recombinant Factor VIIa in plasma from patients with severe haemophilia A. Blood (2002) 99:175-179.
82. SHAPIRO A, GILCHRIST GS, HOOTS WK, COOPER HA, GASTINEAU DA: Prospective randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb. Haemost. (1998) 80:773-778.
83. LUSHER J, INGERSLEV J, ROBERTS H, HEDNER U: Clinical experience with recombinant Factor VIIa. Blood Coagul. Fibrinolysis (1998) 9:119-128.
84. SCHARRER I: Recombinate Factor VIIa for patients with inhibitors to Factor VIII or IX or Factor VII deficiency. Haemophilia (1999) 5:253-259.
85. INGERSLEV J: Efficacy and safety of recombinant Factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilia patients with Factor VIII and Factor IX inhibitors. Semin. Thromb. Haemost. (2000) 26:425-432.
86. HEDNER U, GLAZER S, FALCH J: Recombinant activated Factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus. Med. Rev. (1993) 7:78-83.
87. SANTAGOSTINO E, GRINGERI A, MANNUCCI PM: Home treatment with recombinant activated Factor VII in patients with Factor VIII inhibitors: the advantages of early intervention. Br. J. Haematol. (1999) 104:22-26.
88. LAURIAN Y, GOUDEMAND J, NEGRIER C et al.: Use of recombinant activated Factor VII as first line therapy for bleeding episodes in haemophilaics with Factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul. Fibrinolysis (1998) 9:S107-S110.
89. KEY NS, ALEDORT LM, BEARDSLEY D et al.: Home treatment of mild to moderate bleeding episodes using recombinant activated Factor VII (Novoseven) in haemophiliacs with inhibitors. Thromb. Haemost. (1998) 80:912-918.
90. LLOYDS-JONES M, WIGHT J, PAISLEY S, KNIGHT C: Control of bleeding in patients with haemophilia A with inhibitors:a systematic review. Haemophilia (2003) 9:464-520.
91. JURLANDER B, THIM L, KLAUSEN NK et al.: Recombinant activated Factor VII (rFVIIa): characterization, manufacturing and clinical development. Semin. Thromb. Haemost. (2001) 27:373-383. • A review on the mechanism of action and the clinical use of rFVIIa.
92. SIDDIQUI MA, SCOTT LJ: Recombinant Factor VIIa (eptacog alfa). A review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs (2005) 65:1161-1177.
93. KENET G, LUBETSKY A, LUBOSHITZ J et al.: A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated Factor VII (Novoseven). J. Thromb. Haemost. (2003) 1:450-455.
94. PARAMESWARAN R, SHAPIRO AD, GILL JC, KESSLER CM: Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the hemophilia and thrombosis research society. HTRS Registry Investigators. Haemophilia (2005) 11:100-106.
95. KAVAKLI K, MAKRIS M, ZULFIKAR B, ERHARDTSEN E, ABRAMS ZS, KENETT G: Home treatment of haemarthroses using a single dose regimen of recombinant activated afctor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. NovoSeven Trial (F7 HEAM-510) Investigators. Thromb. Haemost. (2006) 95:600-605.
96. SCHULMAN S, BECH-JENSEN M, VARON D et al.: Feasibility of using recombinant Factor VIIa in continuous infusion. Thromb. Haemost. (1996) 75:432-436.
97. LUDLAM CA, SMITH MP, MORFINI M et al.: A prospective study of recombinant activated Factor VII administered by continuous infusion to inhibitor patients undergoing elective major otrhopaedic surgery: a pharmacokinetic and efficacy evaluation. Br. J. Haematol. (2003) 120:808-813.
98. SANTAGOSTINO E, MORFINI M, ROCINO A et al.: Relationship between Factor VII activity and clinical efficacy of recombinant afctor VIIa given by continuous infusion to patients with Factor VIII inhibitors. Thromb. Haemost. (2001) 86:954-958.
99. SORENSEN B, INGERSLEV J: Whole blood clot formation phenotypes in haemophilia A and rare coagulation disorders. Patterns of response to recombinant Factor VIIa. J. Thromb. Haemost. (2004) 2:102-110.
100. DARGAUD Y, BORDET JC, TRZECIAK MC, VINCIGUERRA C, NEGRIER C: A case of Glanzmann's thrombasthenia successfully treated with recombinant FVIIa during a surgical procedure: observations on the monitoring and the mechanismof action of this drug. Haematologica (2006) 91(1):17-20.
101. FULCHER CA, DE GRAAF MAHONEY S, ZIMMERMANN TS et al.: FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood (1987) 69:1475-1480.
102. FREEDMAN J, GARVEY MB: Immunoadsorption of Factor VIII inhibitors. Curr. Opin. Hematol. (2004) 11:327-333. • A discussion on the use of the immunoabsorption of FVIII inhibitors.
103. RIVARD GE: Use of protein A column and porcine Factor VIII. Haemophilai (2002) 8(Suppl. 1):20-23.
104. BRACKMANN HH, GORMSEN J: Massive Factor VIII infusion in haemophiliac with Factor VIII inhibitor, high responder. Lancet (1977) 2(8044):933.
105. MORFINI M, LEE M, MESSORI A: The design and analysis of half-life and recovery studies for Factor VIII and Factor IX. Facror VIII/Facror IX Scientific and Standardization Commitee of the International Society for Thrombosis and Haemostasis. Thromb. Haemost. (1991) 66:384-386.
106. DIMICHELE DM, KRONER B; THE NORTH AMERICAN IMMUE TOLERANCE STUDY GROUP: The North American Immue Tolerance Registry: practices, outcomes, outcome predictors. Thromb. Haemost. (2002) 87:52-57. • A report on the immune tolerance practices and outcomes in haemophilia patients.
107. ACHARYA SS, DIMICHELE DM: Management of Factor VIII inhibitors. Best Pract. Res. Clin. Haematol. (2006) 19:51-66.
108. ASTERMARK J, MORADO M, ROCINO A et al.: Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia (2006) 12:363-371.
109. BERNTORP E: Immune tolerance induction: recombinant versus human-derived product. Haemophilia (2001) 7:109-113.
110. KREUZ W, ETTINGSHAUSEN CE, ZYSCHKA A et al.: Inhibitor development in previously untreated patients with haemophila A: a prospective long-term follow-up comparing plasma derived and recombinant products. Semin. Thromb. Haemost. (2002) 28:285-290.
111. GRINGERI A, MANNUCCI PM: Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. For Italian Association of Haemophilia Centres. Thromb. Haemost. (2005) 11:611-619.
112. STASI R, BRUNETTI M, STIPA E, AMADORI S: Selective B cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood (2004) 103:4424-4428.
113. CARCAO M, ST LOUIS J, POON MC et al.: Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. On behalf of the Inhibitor Subcommittee of the Association of Haemophilia Clinic Directors of Canada. Haemophilia (2006) 12:7-18.
114. MATHIAS M, KHAIR K, HANN I et al.: Rituximab in the treatment of alloimmune Factor VIII and IX antibodies in two children with severe haemophilia. Br. J. Haematol. (2004) 125:366-368.
115. PIPE SW: The promise and challenges of bioengineered recombinant clotting factors. J. Thromb. Haemost. (2005) 3:1692-701.
116. MIAO HZ, SIRANCHAINAN N, PALMER L et al.: Bioengineering of coagulant FVIII for improved secretion. Blood (2004) 103:3412- 3419.
117. SAENKO EL, PIPE SW: Strategies towards a longer acting Factor VIII. Haemophilia (2006) 12(Suppl. 3):42-51. • A nice discussion of the bioengineering of FVIII and FIX.
118. MOLINEUX G: Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy (2003) 23:3S-8S.
119. BARU M, CARMEL-GOREN L, BARENHOLZ Y et al.: Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thromb. Haemost. (2005) 93:1061-1068.
120. PIPE SW, KAUFMAN RJ: Characterization of a genetically engineered inactivation resistant coagulation Factor VIIIa. Proc. Natl. Acad. Sci USA (1997) 94:11851-6.
121. SAENKO EL, YAKHYAEV AV, MIKHAILENKO I et al.: Role of the low density lipoprotein-related protein receptor in mediation of Factor VIII catabolism. J. Biol. Chem. (1999) 274:37685-92.
122. BOVENSCHEN N, MERTENS K, HU L et al.: LDL receptor cooperates with LDL receptor related protein in regulating plasma levels of coagulation Factor VIII in vivo. Blood (2005) 106:906-912.
123. LUBIN IM, HEALEY JF, BARROW RT, SCANDELLA D, LOLLAR P: Analysis of the human Factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J. Biol. Chem. (1997) 272:30191-30195.
124. BARROW RT, HEALEY JF, GAILANI D, SCANDELLA D, LOLLAR P: Reduction of antigenicity of FVIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine Factor VIII molecules. Blood (2000) 95:564-568.
125. GRAW J, BRACKMANN HH, OLDENBURG J, SCHNEPPENHEIM R, SPANNAG M, SCHWAAB R: Haemophilia A: from mutation analysis to new therapies. Nature (2005) 6:488-501.
126. NATHWANI AC, BENJAMIN R, NIENHUIS AW, DAVIDOFF AM: Current status and prospects for gene therapy. Vox Sanguinis (2004) 87:73-81.
127. LILLICRAP D, VANDENDRIESSCHE T, HIGH K: Cellular and genetic therapies for haemophilia. Haemophilia (2006) 12(Suppl. 3):36-41. •• An excellent review of cellular and gene therapy for haemophilia.
128. HIGH KA, MANNO CS, SABATINO DE et al.: Immune responses to AAV and to FIX in a Phase I study of AAV mediated, liver directed gene transfer for hemophilia B. Blood (2003) 102:154a.
129. KAZAZIAN HH JR: An estimated frequency of endogenous insertional mutations in humans. Nat. Genet. (1999) 22:130.
130. EHRHARDT A, KAY MA: A new adenoviral helper dependent vector results in long term therapeutic levels of human coagulation Factor IX at low doses in vivo. Blood (2002) 99:3923-3930.
131. HACEIN BEY ABINA S, VON KALLE C, SCHMIDT M et al.: LMO2 associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302:415-419.
132. SORENSEN B, INGERSLEV J: Thromboelastography and recombinant Factor VIIa hemophilia and beyond. Semin. Hematol. (2004) 41(Suppl. 1):140-144.
133. SORENSEN B, INGERSLEV J: Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thromboelastography. Haemophilia (2005) 11:1-6.
134. SIEGEMUND T, PETROS S, SIEGEMUND A et al.: Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb. Haemost. (2003) 90(5):781-786.
135. HEMKER HC, GIESEN P, AL DIERI R et al.: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol. Haemost. Thromb. (2003) 33:4-15.
136. DARGAUD Y, BEGUIN S, LIENHART A et al.: Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb. Haemost. (2005) 93:475-480.
137. DARGAUD Y, BORDET JC, BAGLIN T et al.: Monitoring of FVIII-FIX by-passing agents by calibrated automated thrombin generation test. Haematologica (2006) 12(Suppl. 2):14 (Abstract PO 376).
138. KAY MA, MANNO CS, RAGNI MV et al.: Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. (2000) 24(3):257-261.
139. ROTH DA, TAWA NE JR, O'BRIEN JM et al.: Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. Factor VIII Transkaryotic Therapy Study Group. N. Engl. J. Med. (2001) 344:1735-1742.
140. POWELL JS, RAGNI MV, WHITE GC 2ND et al.: Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood (2003) 102:2038-2045.
141. MANNO CS, MANNO CS, ARRUDA VR et al.: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. (2006) 12:342-347.
142. JIANG H, PIERCE GF, OZELO MC et al.: Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther. (2006) 14:452-455.
143. LU DR, ZHOU JM, ZHENG B et al.: Stage I clinical trial of gene therapy for hemophilia B. Sci. China B (1993) 36:1342-1351.